TLDR Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.
The study explored the effectiveness of oral tacrolimus in treating corticosteroid-refractory alopecia totalis. The research was conducted by the Department of Dermatology at Princess Alexandra Hospital NHS Trust in Essex, UK. The findings suggested that oral tacrolimus could be a viable treatment option for patients who did not respond to corticosteroids, offering a potential alternative for managing this severe form of hair loss. However, the document did not provide specific details on the number of participants or the statistical outcomes, which are crucial for evaluating the strength of the study's conclusions.
Cited in this study
5 / 5 results
184 citations
,
April 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
47 citations
,
November 2014 in “Expert Opinion on Emerging Drugs” New alopecia treatments aim for better results and fewer side effects.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
71 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.
218 citations
,
May 2012 in “British Journal of Dermatology” Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.
1 citations
,
April 2017 in “Journal of dermatological treatment” Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.
